Drawing for VERANCE

USPTO serial 97746376

VERANCE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
CRAVEN, PAUL S
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VERANCE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christina M. Licursi

Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210-2206UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disordersACTIVE
042Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; scientific research in the field of drug discovery and development; biomedical research services; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug developmentACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 6, 2025MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 6, 2025ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 4, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 2, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 2, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 13, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 22, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Feb 21, 2024XAECEXAMINER'S AMENDMENT ENTERED
Feb 21, 2024ALIEASSIGNED TO LIE
Feb 21, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 21, 2024GNEAEXAMINERS AMENDMENT E-MAILED
Feb 21, 2024CNEAEXAMINERS AMENDMENT -WRITTEN
Feb 16, 2024MREINOTICE OF REINSTATEMENT E-MAILED
Feb 12, 2024RGIAREINSTATEMENT GRANTED - INADVERTENTLY ABANDONED
Feb 12, 2024MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Feb 12, 2024ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 27, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 27, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 28, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 28, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 28, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 21, 2023DOCKASSIGNED TO EXAMINER
Jan 31, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2023NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance